Background. Carriage of Mycoplasma pneumoniae (Mp) in the nasopharynx is considered a prerequisite for pulmonary infection. It is interesting to note that Mp carriage is also detected after infection. Although B cells are known to be involved in pulmonary Mp clearance, their role in Mp carriage is unknown.
Mycoplasma pneumoniae (Mp) is a frequent cause of childhood community-acquired pneumonia (CAP) worldwide [1] , and it is currently the most commonly detected bacterial cause of CAP in hospitalized children in the United States [2] . We and others [3] [4] [5] [6] [7] observed that, in addition to causing upper respiratory tract (URT) and lower respiratory tract (LRT) infections, Mp is also carried in the URT of asymptomatic children. Carriage is considered a prerequisite for infection [3, [8] [9] [10] . It is interesting to note that carriage also occurs after symptomatic infection [11] . Several studies in humans demonstrated the presence of Mp in the nasopharynx up to 8 months after respiratory tract infection [3] [4] [5] [6] [7] .
B cells are of crucial importance for the host defense against multiple pathogens, because B cell activation can result in the production of specific immunoglobulins (Igs) that neutralize the pathogen [12] . After an initial Mp respiratory tract infection, Mp-specific IgM is detectable in serum within 1 week, and increased amounts of Mp-specific IgG can be found from 2 weeks postinfection (p.i.) [13, 14] . Mycoplasma pneumoniae-specific IgA is produced early after infection, and its levels both peak and decrease earlier than IgM or IgG [15] . Indeed, B cells are known to be involved in pulmonary Mp clearance [16] [17] [18] [19] [20] . Furthermore, patients with hypogammaglobulinemia are at greater risk for Mp pulmonary disease and/or extrapulmonary manifestations [21] [22] [23] [24] [25] . It is likely that carriage of Mp by these patients make them susceptible to the development of symptomatic Mp infection.
In contrast to the known important role of B cells in clearance of a pulmonary infection, there is limited knowledge on the role of B cells in the control of Mp carriage in the URT. Therefore, we set out to determine whether humoral immunity contributes to clearance of Mp carriage from the URT. Because this is difficult to study in human subjects, we further developed a C57BL/6 mouse model to study Mp (strain M129) infections and the role of humoral immunity on control of these infections.
Experiments Committee of the Erasmus MC (Rotterdam, The Netherlands).
Bacteria
Mycoplasma pneumoniae reference strain M129 (subtype 1, ATCC 29342) was cultured at 37°C/5% CO 2 in SP4 medium (pH 7.8-8.0) for 72 hours and concentrated in fresh SP4 medium to 1 × 10 9-10 colony-forming units (CFU)/mL (Supplementary Data). To track Mp, bacteria were labeled with 10 μM carboxyfluorescein diacetate succinimidyl ester (CFSE) according to the manufacturer's instructions (Molecular Probes).
Mycoplasma pneumoniae Infection and Carriage Mouse Model
Mice were inoculated intranasally with 1 × 10 9 CFU of M129 diluted in 50 µL SP4 medium. Control mice were inoculated with 50 µL SP4 medium. On indicated days after Mp inoculation, body weight was measured and mice were sacrificed. Lung washes and nasal fluid samples (washes and brushes) were collected. Cells from lungs, lymph nodes, and nasal passages (mucosa and nasal-associated lymphoid tissue [NALT] [27] ) were isolated. Detailed methods for sample procedures are included in the Supplementary Data.
Serum Transfer
Sera were collected and pooled from wild-type (WT) and µMT mice on day 14 p.i. and diluted with phosphate-buffered saline (1:1.3), and 200 μL was injected intravenously into each WT and µMT recipient mice at day 15, 16, and 22 p.i. One week after the last serum transfer, recipient mice were sacrificed. Sera were devoid of Mp as confirmed by a negative polymerase chain reaction (PCR) for Mp [28] .
Mycoplasma pneumoniae Quantification
The presence of Mp was detected either by PCR [28] or culture of bronchoalveolar lavage fluids (BALFs) and nasal fluid samples (100 µL undiluted and 10-fold diluted) on SP4 agar plates at 37°C. Suspensions of spleen, liver, and immersed cotton swabs of articular surfaces were processed in a similar fashion.
Mycoplasma pneumoniae Phagocytosis and Killing
Mycoplasma pneumoniae M129 was incubated with sera from infected WT mice. Sera from uninfected mice were used as the control. Murine RAW 264.7 macrophages were incubated with the respective bacteria for 20 minutes and washed, and at time point of 0 and 180 minutes, cells were lysed to determine bacterial load (CFU/10 5 RAW cells) by culture on SP4 agar plates.
Histopathology Scoring
Histopathology scoring (HPS) of lung sections was performed without knowledge of the treatment or time after infection of mice. The modified HPS system [29] assigns values from 0 to 10 by grading immune cell infiltrates in alveoli and bronchi for distribution, severity of inflammation, presence of necrosis, and presence of perivascular, peribronchial, and peribronchiolar cuffing (Supplementary Data).
Quantification of Antibodies
Total antibody concentrations (micrograms/milliliter) and Mp-specific antibodies (arbitrary units [AU]/milliliter) were quantified by enzyme-linked immunosorbent assay (ELISA), as described in the Supplementary Data.
Immunoglobulin A Antibody-Secreting Cells Enzyme-Linked

Immunospot Assay
The frequency of Mp-specific and total IgA-producing antibody secreting cells (ASCs) in mediastinal lymph nodes (MLNs), cervical mediastinal lymph nodes (CLNs), and nasal passages was measured by an enzyme-linked immunospot (ELISpot) assay using a commercially available kit (Mabtech), as described in the Supplementary Data.
Flow Cytometry
Aliquots of single-cell suspensions were incubated with appropriate dilutions of antibodies for 30 minutes on ice. Cells were subsequently analyzed using FACS Canto II (BD Biosciences) and FlowJo 10 software (Tree Star). Monoclonal antibodies and the gating strategy are described in Supplementary Figure S1 .
Cytokine Analysis
Cytokines were measured in BALF and nasal lavage fluid by a multiplex fluorescent-bead-based immunoassay (ProcartaPlex multiplex; eBioscience).
Statistical Analysis
R software environment (version 3.4.0) and GraphPad Prism (version 5.01) were used for statistical analysis. The Welch's t test, Mann-Whitney U test, Kruskal-Wallis test with post hoc Dunn's multiple comparisons test of selected pairs, Fisher exact test, or χ 2 test were used to determine statistical significance. Family-wise error rates were controlled using the HolmBonferroni method. Association between paired samples was tested using the Pearson's product moment correlation coefficient. Statistical significance was defined as P < .05.
RESULTS
Mycoplasma pneumoniae Persists in the Nose After
Pulmonary Infection
To unravel the role of B cells in Mp pulmonary infection and nasal carriage, we further developed a mouse model for Mp infection using the Mp reference strain M129 (subtype 1) in C57BL/6 mice [30] [31] [32] . Intranasal inoculation of anaesthetized C57BL/6 mice with 1 × 10 9 CFU of Mp M129 resulted in a mean relative body weight loss of 4% within 3 days ( Figure 1A ). Afternot control mice, were positive for Mp with the highest median bacterial load of 3 × 10 4 CFU/mL on day 3 p.i. (Figure 1B ). Bacterial loads in BALF gradually declined within 2 weeks and were undetectable at 4 weeks after infection. In contrast to the lung, Mp persisted in the nose. During the first 2 weeks of infection, median bacterial loads were 5-9 × 10 4 CFU/mL, and at day 42 p.i., Mp was still detected in the nasal lavage fluid of 5 of 6 mice, with a median bacterial load of 6 × 10 2 CFU/mL ( Figure 1C ). The only mouse in which Mp was not detected in the nasal lavage fluid at day 42 p.i. did show a positive culture for Mp when nasal brush samples were analyzed (data not shown).
These findings were corroborated using CFSE-labeled Mp M129: CFSE-labeled bacteria were detected on the bronchial epithelium and in alveoli-forming islets in the lungs at day 1 p.i. (Figure 1D ). The loss of fluorescence from the lungs of infected mice at day 3 p.i. likely resulted from bacterial replication, because high bacterial loads were detected in the lungs at this same time point ( Figure 1B) , and CFSE signals are reduced 2-fold at each bacterial division [33] . This was confirmed when sections were incubated with an anti-Mp antibody: Mp was detected in the lungs both at day 1 and day 3 p.i. (data not shown). By contrast, CFSE-labeled Mp was detected on the nasal respiratory epithelium at both time points analyzed, without an apparent loss of fluorescence intensity between these time points ( Figure 1E ). In contrast to previous studies showing invasion and intracellular survival of Mp in vitro [34, 35] , we did not observe CFSE-labeled Mp within respiratory epithelial cells (Supplementary Figure S2) .
Specific Immunoglobulin G Antibodies in Serum and Bronchoalveolar
Lavage Fluids Coincide With Clearance of Mycoplasma pneumoniae From the Lungs
To define the course of pneumonia after infection with Mp and identify immune mechanisms that contribute to pulmonary clearance, we examined pulmonary inflammation by HPS as well as immune cells and antibodies in BALF at the indicated time points after inoculation of mice with Mp. Pulmonary inflammation, demonstrated by both inflammatory infiltrates and necrosis in HPS ( Figure 2A ) and increased BALF leukocytes (Supplementary Figure S3A) , was most severe on day 3 p.i. and resolved at day 28 p.i. At day 3 p.i., the infected lungs showed pulmonary consolidation at gross pathology, and histopathology showed thickened alveolar septa characterized by infiltration of inflammatory infiltrates and presence of perivascular and peribronchiolar cuffing ( Figure 2B ). Using flow cytometry, we detected a major influx of granulocytes, monocytes, and dendritic cells into BALF at day 3 p.i. (Supplementary Figure  S3B) , which corroborated the inflammation seen histologically at that time point (Figure 2 ). In addition, increased numbers of CD4 + and CD8 + T cells, NK cells, and B cells were detected in infected lungs, albeit at much lower frequencies than observed for the innate immune cells (Supplementary Figure S3C) . Because B cells only marginally infiltrated the lungs, we evaluated the systemic and local humoral immune response against Mp. Both Mp-specific IgM and IgG were detected in serum from day 7 p.i. (Figure 3A) . Although specific IgM levels declined after day 28 p.i., specific IgG persisted at high levels. Further analysis revealed that both IgG1 and IgG2a subclasses were present in the Mp-specific IgG pool ( Figure 3B ), which indicates neutralizing and complement-dependent killing of Mp. Indeed, we found that the serum of Mp-infected WT mice had the capacity to opsonize Mp, resulting in enhanced internalization and killing of the bacteria by macrophages in vitro ( Figure 3C ).
It is notable that Mp-specific IgG levels in the nasal lavage fluid were far below those detected in BALF on day 42 ( Figure 4A ). The opposite was seen for specific IgA: the levels were highly increased in nasal lavage fluid but not in BALF. Total IgG and IgA levels were similar in BALF and nasal lavage fluid (Supplementary Figure S4) . The ELISpot analysis revealed that Mp-specific IgA ASCs were present in CLN and nasal passages 7 days p.i., with the highest numbers in CLN ( Figure 4B ).
In contrast and in line with the data obtained by ELISA, Mp-specific IgA ASCs were not present in MLN.
This prompted us to investigate the activation and expansion of B cells in the CLN and MLN that drain the URT and LRT, respectively. B cell expansion and activation was observed in both MLNs and CLNs, but not in peripheral (inguinal) lymph nodes (PLNs), which indicates that Mp infection induced a B cell response only locally and not systemically ( Figure 4C and D) . It is interesting to note that the expression levels of CD86 were higher on B cells in MLN than on those in CLN ( Figure 4E ). It is notable that increased numbers of CD86 + B cells were still found in CLN, but not in MLN, on day 28 p.i., albeit not significant from controls. Together, these findings demonstrate a distinct difference in the B cell response to Mp between LRT and URT lymphoid tissues.
B Cells Are Essential for Pulmonary Clearance of Mycoplasma pneumoniae and Affect Carriage
To further evaluate the contribution of B cells to protective immunity against Mp, we assessed whether bacterial replication in the URT and LRT is altered in B cell-deficient μMT mice. Similar to WT mice, an initial body weight loss at day 3 p.i. was measured in μMT mice. Yet, although infected WT mice were back at their initial weight within 2 weeks and from then on continued to gain weight, the weight of μMT mice remained lower than that of WT mice at all time points analyzed ( Figure  5A ). It is interesting to note that although Mp was no longer detectable in BALF of WT mice at day 28 p.i., bacteria were still detectable at day 42 in μMT mice, albeit at relatively low levels ( Figure 5B ). In the absence of antibodies, mycoplasma is suggested to be more prone to disseminate extrapulmonary [16] [17] [18] ; however, spleen, liver, and articular surfaces of μMT and WT mice on day 14 and 28 p.i. were negative for Mp by culture and PCR (data not shown).
In line with the long-term presence of Mp in the lungs of μMT mice, both the HPS of alveoli ( Figure 5D ) and the lung leukocyte number ( Figure 5E ) of μMT mice were higher than those of WT mice on day 3 p.i. Moreover, in comparison with WT mice, the lungs of μMT mice showed even increased numbers of leukocytes on day 42 p.i. (Figure 5E and F) .
In addition, it is interesting to note that significantly reduced control of bacterial replication was observed in the URT of μMT mice ( Figure 5C ). Mycoplasma pneumoniae was detected in nasal lavage fluid of all µMT mice, and the median bacterial loads remained at similar levels from day 14 to 42 p.i. (2 × 10 4 CFU/mL), whereas median bacterial loads in WT mice decreased from 4 × 10 4 to 6 × 10 2 CFU/mL during this time period. In the absence of B cells, significantly higher levels of the proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1 were detected in nasal lavage fluid of μMT mice at day 3 p.i. (Figure 5G ).
Serum Transfer From Wild-Type-Infected Mice to Infected B cell-deficient μMT Mice Controls Bacterial Replication Only in the Lungs
To specifically examine the contribution of the IgG and IgM antibodies in serum to clearance of bacteria from the nose, we passively immunized μMT mice with serum from infected WT mice. Therefore, donor and recipient mice were both intranasally inoculated with 1 × 10 9 CFU of Mp M129. Two weeks later, when recipient WT and μMT mice still had similar median levels of bacterial loads in the lungs (Figure 5B ), donor serum was transferred ( Figure 6A ). As shown in Figure 6B , μMT mice were only able to control Mp replication in the lungs upon transfer of serum from infected WT mice, as indicated by the similar bacterial load in the lungs of μMT and WT mice at day 28 p.i. However, transfer of μMT serum did not reduce Mp loads in the lungs of infected μMT recipient mice; pulmonary Mp loads in these μMT recipients were similar to those of untreated controls at day 28 p.i. (Figure 6B ). Moreover, these findings were corroborated by the detection of Mp-specific IgG in the BALF of 4 of 6 μMT recipient mice 2 weeks after WT serum transfer ( Figure 6D ). Mycoplasma pneumoniae persisted in the lungs of the 2 μMT recipient mice, whose BALF did not contain Mpspecific IgG after serum transfer ( Figure 6E) .
By contrast, the bacterial loads in the nose were comparable for all recipient μMT mice (with a median of 2 × 10 4 CFU/mL), irrespective of the specific source of the serum ( Figure 6C ). The median concentration of Mp-specific and total IgG in nasal lavage fluid of infected μMT mice after serum transfer was 5 AU/mL and 0.005 μg/mL, respectively, at day 28 p.i. It is notable that there was no significant difference between Mp-specific IgG levels in BALF and nasal lavage fluid of μMT mice receiving WT serum (median 6 vs 5 AU/mL). In addition to nasal lavage fluid and BALF, Mp-specific and total IgG antibodies were also detected in serum of μMT mice after WT serum transfer (Supplementary Figure S5) .
DISCUSSION
In this study, we show Mp persistence after infection in a further developed mouse model for Mp infection [30] [31] [32] . B cells in lung-draining MLNs become activated and expand early after Mp infection, resulting in elevated levels of Mp-specific IgM and IgG antibodies in serum and BALF. This B cell activation in MLNs may be key to clear the infection as shown by our observations in μMT mice, in which Mp infection leads to chronic pulmonary disease, characterized by failure to thrive, more severe pneumonia, and long-lasting innate and adaptive compensatory immune cell infiltrates, due to bacterial persistence in the lungs. In contrast, μMT mice do clear Mp infections in the lungs when passively immunized with serum from infected WT mice. In addition, we showed that the induced antibodies enhance phagocytosis and killing by macrophages in vitro, which suggests that they can contribute to resolve Mp infections in vivo.
In contrast to the lungs, B cells in the nose-draining CLNs did not become activated by the presence of Mp. Because the draining lymph nodes are the major sites of B cell induction after respiratory tract infection [36] , the observed differences in B cell expansion and activation between the nose-draining CLNs and lung-draining MLNs suggest a different control of bacterial replication in the URT compared with that in the LRT. Indeed, Mp persisted in the nose of WT mice while the bacterium was cleared from the lungs during the course of infection. More importantly, these data mimic the findings in humans, where Mp is carried in the URT of children up to 8 months after symptomatic infection [3] [4] [5] [6] [7] . The observed difference in B cell responses between LRT and URT lymphoid tissues is in line with the low levels of Mp-specific IgG and IgM in the nasal lavage fluid. It is unlikely that Mp-specific IgG does not reach the URT, because total IgG levels were similar in nasal lavage fluid and BALF, and we observed comparable bacterial loads in the URT of WT mice as in that of Bruton tyrosine kinase (Btk)-deficient mice, which have reduced peripheral B cell numbers (data not shown). In contrast to Mp-specific IgG, Mp-specific IgA was more abundant in nasal lavage fluid than in BALF of Mp-infected mice. Although this has not been shown before for bacterial infections, similar observations were made in influenza virus-infected mice [37] . The vast majority of ASCs in the URT (NALT) of such mice were found to produce IgA, whereas B cell responses in the LRT (lungs) mainly generated IgG and IgM [38] . In fact, we also detected Mp-specific IgA ASCs in CLN and nasal passage, but not in MLN, which is in line with observations from Hodge and Simecka [39] , showing mycoplasma-specific IgA ASCs in nasal passages but not in the lungs from mice after nasal immunization. Furthermore, these data also corroborate our findings on the presence of IgA in nasal washes but not in BALF. pulmonary infection in lungs of μMT mice but did not lead to a reduction of Mp loads in the nose. Together, these observations demonstrate the importance of local immunity. Yet, why IgA cannot clear bacterial carriage in the URT is unknown [40] . Mycoplasma pneumoniae is not known to possess IgA protease activity [41] . In addition, increasing local specific IgA responses by immunization did not lead to a corresponding reduction of mycoplasma bacterial loads in the nose [39] , which suggests that enhancing IgA responses alone does not control carriage in the URT.
Our observation that Mp infections are more severe-and chronic-in µMT mice may resemble the findings in patients that suffer from B cell deficiencies [42] , such as common variable immunodeficiency, X-linked agammaglobulinemia, or hypogammaglobulinemia, who have been reported to be at increased risk for Mp pulmonary disease and/or extrapulmonary manifestations, eg, arthritis [21] [22] [23] [24] [25] . It can be speculated that if these patients experience Mp infections, they may benefit from intravenous immunoglobulin (IVIg) treatment, because our data demonstrate that administration of serum containing Mp-specific IgG enabled µMT mice to clear pulmonary Mp infection. In fact, high amounts of Mp-specific IgG can be detected in commercial human IVIg preparations [43] .
Although the Mp mouse model provides a useful tool to investigate the immunological processes involved in controlling infection of the lungs and carriage in the nose, the use of the human pathogen Mp instead of Mycoplasma pulmonis [44] can be a limitation of our study considering the genomic differences between these pathogens [45] .
CONCLUSIONS
Together, we show for the first time that, similar to that found in humans, Mp is carried in the URT of mice after symptomatic infection. In addition, we demonstrate that B cells and Mpspecific antibodies are crucial for Mp clearance in the lungs of mice but are limited in clearing Mp from the URT. These novel aspects of Mp-host interactions will aid the understanding of Mp pathogenesis and promote the development of Mp-targeting vaccines to prevent the progress of Mp pulmonary disease in individuals who carry Mp.
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